Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- China Sky One to Sell Diagnostic Kits in Southeast Asia
- ChinaBio Today submits: China Sky One Medical (NSDQ: CSKI) has signed up Guangdong Mediacy Kind Medical Devices Industry Service Company to be its exclusive sales agent in Southeast Asia for two of the company’s diagnostic kits: AMI Diagnostic Kit, used to diagnose myocardial infarction, and Human Urinary Albumin Elisa...
- External links 2009-12-02
- China Sky One Starts Production at New Subsidiary
- ChinaBio Today submits: China Sky One Medical CSKI announced that production has started at the Peng Lai Jin Chuang company facility. China Sky One finalized the acquisition of Jin Chuang last month, paying $7.1 million in cash and stock to gain control of the company. Jin Chuang...
- External links 2008-10-15
- WuXi Misses Q3 Forecast, Guides Lower for Year
- ChinaBio Today submits: WuXi PharmaTech WX released weaker-than-expected financial Q3 results unaudited and, at the same time, lowered guidance for its full year. The company reduced its forecast for 2009 revenue by $20 to $35 million. The new revenue range is expected to be between $260 and $265 million,...
- External links 2008-10-15
- WuXi Expands J&J Collaboration
- ChinaBio Today submits: WuXi PharmaTech WX announced that is has expanded its collaboration with Johnson & Johnson JNJ. According to the release, WuXi will provide Janssen Pharmaceutica, a division of J&J Pharmaceutical Research & Development, with integrated research services in the area of discovery chemistry, discovery biology, chemical and...
- External links 2008-10-16
- China Biologic Buys Another Plasma-Based Pharma
- ChinaBio Today submits: China Biologic Products, Inc. (CBPO.OB) continued its acquisitive path by announcing its intention to purchase a 35% stake in Xi'an Huitian Blood Products Co., Ltd. Both company manufacture plasma-based pharmaceuticals. China Biologic will pay 44 million RMB ($6.4 million) for the purchase of Huitian, the only...
- External links 2008-10-17
- American Oriental Announces Two Acquisitions
- ChinaBio Today submits: American Oriental Bioengineering, Inc. AOB completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in...
- External links 2008-10-23
- China Sky One Signs Distribution Deal for Asthma Patch
- ChinaBio Today submits: China Sky One Medical CSKI has signed an agreement with Shaanxi Xintai Pharmaceutical Company to distribute its newly approved Asthma Patch product. China Sky One focuses on OTC patch products for the China market. The Asthma Patch is the second product that Shaanxi Xintai...
- External links 2008-10-23
- China Medical Wrestles with Daunting $345 Million Acquisition
- ChinaBio Today submits: China Medical Technologies CMED told investors it would release a preliminary Q2 (ended September 30, 2008) financial report on November 18, but a full announcement, complete with answering questions from analysts, will wait another month until December 18. As reason for the delay, the company said...
- External links 2008-10-27
- China Pharma Gets Green Light for Antibiotics Trial
- ChinaBio Today submits: China Pharma Holdings (CPHI.OB) was given the go-ahead by the SFDA to begin clinical trials of a novel antibiotic combination formula. China Pharma describes the new product as a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor. Its clinical trial will begin in November. ...
- External links 2008-10-30
- China Sky One Adds Breast Lesion Drug to Product Portfolio
- ChinaBio Today submits: China Sky One Medical CSKI has bought a proprietary breast lesion drug from Harbin Medical University for 10 million RMB ($1.5 million). The drug, which China Sky One and Harbin developed jointly, has completed its Phase I trial. In the more than 10,000 patients enrolled in...
- External links 2008-10-30
- Shengtai Pharma Seeks Global Growth
- ChinaBio Today submits: Shengtai Pharmaceutical, Inc. (SGTI.OB) will begin a push to sell its pharmaceutical grade glucose products internationally. To get this done, the company has restructured its international sales team. The company said it already has customers in 70 countries, but according to SEC documents, Shengtai...
- External links 2008-10-31
- China Sky One Expands into Injected Drugs
- ChinaBio Today submits: China Sky One Medical CSKI received SFDA approval for two new products. Sodium ferulate by injection, a TCM found in the root of Angelica sinensis, is indicated for cardiovascular disease. The drug inhibits the gathering of hematoblasts and stretches blood vessels in order to protect cardiac...
- External links 2008-10-31
- Covance Taking China Growth Slowly
- ChinaBio Today submits: Following the collapse of its Joint Venture arrangement with WuXi PharmaTech WX, Covance CVD will build its own China CRO facilities, but the company does not feel any great pressure to get the job done quickly. The reason? China’s current cost advantage will soon disappear, as...
- External links 2008-11-02
- Sinovac Listed in Deloitte Technology Fast 50 China 2008
- ChinaBio Today submits: Sinovac Biotech Ltd. SVA said its main operating entity, Sinovac Beijing, was named to the Deloitte Technology Fast 50 China 2008. A vaccine maker, Sinovac’s revenues derive mainly from its hepatitis A vaccine, Healive. The company also makes a combination hepatitis A & B vaccine, a flu...
- External links 2008-11-04
- 3SBio's Q3 Hurt by Lehman Bankruptcy
- ChinaBio Today submits: 3SBio Inc. SSRX announced a $2.7 million writedown as a consequence of the U.S. financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers...
- External links 2008-11-04
- Tongjitang Shares React Well to Buyback News
- ChinaBio Today submits: Tongjitang Chinese Medicines Company TCM announced its shareholders approved a $20 million share buyback program at the company’s general meeting. The resolution calls for the company to complete a purchase of “up to” $20 million worth of its ADSs within the next 18 months. The program...
- External links 2008-11-04
- Roche Intent on Discovering Innovative Medicines in China
- ChinaBio Today submits: Roche (RHHBY.PK) has broken ground on an expansion of its facilities at its site in Shanghai’s Zhangjiang Hi-Tech Park, an ambitious expansion that seeks to provide the backbone for the next ten years of the company’s China growth. In addition, Roche has established an office for...
- External links 2008-11-04
- Investors Liked What They Saw in Simcere's Q3 Report
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR released very positive unaudited financial results for its third quarter. At the same time, the company said it would begin a $50 million share buyback. At the end of the quarter, Simcere reported cash and short-term investments of 831 million RMB ($122.4...
- External links 2008-11-06
- American Oriental Books Another Solid Quarter
- ChinaBio Today submits: American Oriental Bioengineering AOB announced another solid financial performance in Q3. The company’s revenues rose 62% to $70.6 million, and net income was higher by 38% at $16.5 million or 21 cents per diluted share. According to the company, net income failed to keep pace with...
- External links 2008-11-11
- China Pharma Reports Improved Q3, Accounts Receivable Also Up
- ChinaBio Today submits: China Pharma Holdings (CPHI.OB) reported its Q3 revenues climbed 52% to $12.61 million and net income was up 38% to $4.25 million, which equates to 10 cents per share fully diluted. Growth...
- External links 2008-11-11
- << Previous
- page 1 of 12
- Next >>
Refining Tags
- Seeking Alpha (29 results)
- China Sky One Medical Inc. (26 results)
- Biotech (23 results)
- Sinovac Biotech Ltd. (20 results)
- Finance (19 results)
- Operational Accounting (10 results)
- American Oriental Bioengineering Inc. (10 results)
- Revenue (9 results)
- Healthcare (8 results)
- Beijing Med-Pharm Corp. (8 results)
- Financial Accounting (8 results)
- Pharmaceutical Company (7 results)
- Investment (6 results)
- Pfizer Inc. (6 results)
- Net Income (6 results)
- Mergers & Acquisitions (5 results)
- Business Operations (5 results)
- NeoStem Inc. (5 results)
- Corporate Law (4 results)
- Eli Lilly & Co. (4 results)
- GlaxoSmithKline Plc. (4 results)
- China-Biotics Inc. (4 results)
- GAAP (4 results)
- Drug (4 results)
- Manufacturing (3 results)
- Acquisition (3 results)
- Sales Strategy (3 results)
- Sales (3 results)
- Merck & Co. Inc. (3 results)
- Johnson & Johnson (3 results)
- Pharmaceutical Product Development Inc. (3 results)
- Novartis AG (3 results)
